Trial Profile

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 08 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Dec 2023 Results of post hoc analysis assessing association between the endothelin receptor antagonist atrasentan and pain and prescription of analgesics published in the Kidney International
23 Mar 2023 According to a Chinook Therapeutics media release, data from this study will be presented at the ISN World Congress of Nephrology 2023 on Saturday, April 1, 2023 at 17:00-18:00 ICT.
27 Jul 2022 Results assessing the influence of genetic polymorphisms on atrasentan plasma exposure and pharmacodynamic effects, published in the Clinical Pharmacology and Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com